The Canada Pharmaceutical Market was valued at USD 51.56 billion in 2024, and is projected to reach USD 76.9 billion by 2030, rising at a CAGR of 7.00%. Several driving factors influence this significant and highly regulated industry. One of the primary drivers is Canada's aging population. With a growing number of seniors, there's a heightened demand for pharmaceuticals and healthcare services. For example, medications for conditions like osteoarthritis and Alzheimer's are in high demand due to the aging demographic.
Government regulation also plays a crucial role in shaping the pharmaceutical market. Health Canada, the country's regulatory body, oversees drug safety and efficacy. For instance, the approval and regulation of prescription drugs like insulin and antibiotics ensure the quality and safety of medicines available in the market. Research and development (R&D) efforts are another crucial factor. Canada boasts a strong R&D sector, with pharmaceutical companies like Apotex and Valeo Pharma conducting innovative research. For example, developing biologic drugs for conditions like cancer and autoimmune diseases benefits patients and contributes to economic growth.
Moreover, product launches by key players in the market will further propel the Canadian pharmaceutical market growth in the forecast period. For instance, the approval of Arexvy, a respiratory syncytial virus (RSV) vaccine, for individuals aged 60 and older is a significant development in Canada's healthcare landscape. RSV is a common cause of lower respiratory tract disease (LRTD) in older adults, making this vaccine a valuable addition to the preventive measures available. This approval expands the vaccine portfolio of GSK in Canada and addresses a specific healthcare need for the aging population. Introducing Arexvy is especially noteworthy as it marks the first approval of the RSV vaccine for older adults in the country. RSV can lead to severe respiratory illnesses, and older adults are a particularly vulnerable demographic.
This product will be delivered within 2 business days.
Government regulation also plays a crucial role in shaping the pharmaceutical market. Health Canada, the country's regulatory body, oversees drug safety and efficacy. For instance, the approval and regulation of prescription drugs like insulin and antibiotics ensure the quality and safety of medicines available in the market. Research and development (R&D) efforts are another crucial factor. Canada boasts a strong R&D sector, with pharmaceutical companies like Apotex and Valeo Pharma conducting innovative research. For example, developing biologic drugs for conditions like cancer and autoimmune diseases benefits patients and contributes to economic growth.
Moreover, product launches by key players in the market will further propel the Canadian pharmaceutical market growth in the forecast period. For instance, the approval of Arexvy, a respiratory syncytial virus (RSV) vaccine, for individuals aged 60 and older is a significant development in Canada's healthcare landscape. RSV is a common cause of lower respiratory tract disease (LRTD) in older adults, making this vaccine a valuable addition to the preventive measures available. This approval expands the vaccine portfolio of GSK in Canada and addresses a specific healthcare need for the aging population. Introducing Arexvy is especially noteworthy as it marks the first approval of the RSV vaccine for older adults in the country. RSV can lead to severe respiratory illnesses, and older adults are a particularly vulnerable demographic.
Canada Pharmaceutical Market Report Highlights
- By disease, the cancer segment led the market with the largest revenue share of 18.1% in 2024, attributed to the increasing prevalence of cancer and the ongoing development of advanced treatments.
- The parenteral segment is set to experience the fastest growth during the forecast period, fueled by the increasing demand for injectable medications.
- By formulation, the tablets segment accounted for the largest market share in 2024 due to their convenience, affordability, and ease of administration.
- The sprays segment is anticipated to grow at the fastest CAGR from 2025 to 2030, propelled by their user-friendly nature and precise dosing capabilities.
- By end use, the hospitals segment held the largest market share in 2024, propelled by the increasing number of hospitals, leading to higher demand for pharmaceutical drugs to treat various medical conditions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Canada Pharmaceutical Market Variables, Trends, & Scope
Chapter 4. Canada Pharmaceutical Market: Drug Type Business Analysis
Chapter 5. Canada Pharmaceutical Market: Product Business Analysis
Chapter 6. Canada Pharmaceutical Market: Type Business Analysis
Chapter 7. Canada Pharmaceutical Market: Disease Business Analysis
Chapter 8. Canada Pharmaceutical Market: Route of Administration Business Analysis
Chapter 9. Canada Pharmaceutical Market: Formulation Business Analysis
Chapter 10. Canada Pharmaceutical Market: Age Group Business Analysis
Chapter 11. Canada Pharmaceutical Market: End Use Business Analysis
Chapter 12. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies featured in this Canada Pharmaceutical market report include:- F. Hoffmann-La Roche Ltd
- Novartis AG
- GSK plc
- Pfizer Inc.
- Merck & Co., Inc.
- AstraZeneca
- Johnson & Johnson Services, Inc.
- Sanofi
- Eli Lilly and Company
- AbbVie Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 119 |
Published | May 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 51.56 Billion |
Forecasted Market Value ( USD | $ 76.9 Billion |
Compound Annual Growth Rate | 7.0% |
Regions Covered | Canada |
No. of Companies Mentioned | 11 |